|
Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5 alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
|
| United States Patent |
5,510,351 |
| Graham, et. al. |
* Apr. 23, 1996 |
Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5
alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and
treatment of hyperandrogenic disorders
| Inventors: |
Graham; Donald W. (Mountainside, NJ); Aster; Susan D.
(Teaneck, NJ); Tolman; Richard L. (Warren, NJ). |
| Assignee: |
Merck & Co., Inc. (Rahway, NJ). |
| [*]Notice: |
The portion of the term of this patent subsequent to Nov. 10, 2014 has
been disclaimed. |
| Appl. No.: |
338,490 |
| Filed: |
Nov. 14, 1994 |
| PCT Filed: |
May 17, 1993 |
| PCT No: |
PCT/US93/04630 |
| 371 Date: |
Nov. 14, 1994 |
| 102(e) Date: |
Nov. 14, 1994 |
| PCT Pub. No.: |
WO93/23051 |
| PCT Pub. Date: |
Nov. 25, 1993 |
Related U.S. Application Data
| Continuation-in-part of Ser No. 886,050, May 20, 1992, abandoned. |
| Intl. Cl. : |
A61K 31/58 |
| Current U.S. Cl.: |
514/253; 514/241; 514/261; 514/269; 514/284; 544/198;
544/242; 544/264; 544/336; 546/77 |
| Field of Search: |
546/77; 514/284, 253; 544/336 |
References Cited | [Referenced
By:]
U.S. Patent Documents
| 4,220,775 |
Sept., 1980 |
Rasmusson et al. |
546/77 |
| 4,337,584 |
Mar., 1983 |
Rasmusson et al. |
546/77 |
| 4,596,812 |
Jun., 1986 |
Chidsey, III et al. |
|
| 4,732,897 |
Mar., 1988 |
Cainelli et al. |
546/77 |
| 4,760,071 |
Jul., 1988 |
Rasmusson et al. |
546/71 |
| 4,859,681 |
Aug., 1989 |
Rasmusson et al. |
546/77 |
| 4,882,319 |
Nov., 1989 |
Holt et al. |
514/71 |
| 4,888,336 |
Dec., 1989 |
Holt et al. |
546/77 |
| 4,910,226 |
Mar., 1990 |
Holt et al. |
514/319 |
| 5,049,562 |
Sept., 1991 |
Rasmusson et al. |
546/77 |
| 5,084,574 |
Jan., 1992 |
Bhattacharya et al. |
|
| 5,110,939 |
May, 1992 |
Holt et al. |
|
| 5,116,983 |
May, 1992 |
Bhattacharya et al. |
|
| 5,120,742 |
Jun., 1992 |
Rasmusson et al. |
514/284 |
| 5,175,155 |
Dec., 1992 |
Juniewicz et al. |
514/284 |
Foreign Patent Documents
| 0004949 |
Oct., 1979 |
EP |
|
| 0200859 |
Nov., 1986 |
EP |
|
| 0277002 |
Jun., 1988 |
EP |
|
| 1465544 |
Nov., 1965 |
FR |
|
| WO93/23039 |
Nov., 1993 |
WO |
|
| 94/00125 |
Jan., 1994 |
WO |
|
- Other References
- Burger, "Medicinal Chemistry 2d Ed" Interscience N.Y., 1960 p. 42.
Stinson
"Prostate Drug Proscar Cleared for Marketing", Chem & Engineering News, Jun.
29, 1992, pp. 7-8.
Diani et al., "Hair Growth Effects of Oral Administration of Finasteride, A
Steroid 5a-Reductase Inhibitor, Alone and in Combination with Topical Minoxidil in the
Balding Stumptail MaCaque", J. Clin. & Endoc. & Metab. 74: 345-350 (1992).
Geldof "Consideration of the use of 17Beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5
alpha androstan-3-one (4MA) a 5 alpha-reductase inhibitor in prostate cancer therapy"
J. Cancer Res. Clin. Oncol. 118: 50-55 (1992).
Rasmusson, et al., "Azasteroids as Inhibitors of Rat Prostatic 5-alpha
Reductase" J. Med. Chem. 27: 1690-1701 (1984).
Rasmusson, et al., "Azasteroids, Structure Activity Relationships for Inhibition
of 5a-Reductase and of Androgen Receptor Binding" J. Med. Chem. 29: 2298-2315 (1986).
Helliker "Alopecia Sufferers Seek to Suffer Less and not in
Silence", Wall Street Jour. 7 Jun. 1991, pp. A1 & A7.
Back, "Oxidation of Azasteroid Lactams and Alcohols with Benzeneselenic
Anhydride", J. Org. Chem. 46: 1442-1446 (1981).
Back et al., "N-Chloroazasteroids: A Novel Class of Reactive Steroid Analogues.
Preparation, Reaction with Thiols, and Photochemical Conversion to Electrophilic N-Acyl
Imines" J. Organic Chem. 541: 1904-1910 (1989).
Kadohama et al., "Retardation of Prostate Tumor Progression in the Noble Rat by
4-Methyl-4-aza-Steroidal Inhibitors of 5alpha-reductase", JNCI, 74(2): 475-486
(1985).
Liang et al., "Species Differences in Prostatic 5alpha-Reductase of Rat, Dog and
Human", Endocrinology 117(2): 571-579 (1985).
Brooks et al., "Prostatic Effects Induced in Dogs by Chronic or Acute Oral
Administration of 5alpha-Reductase Inhibitors", The Prostate 9: 65-75 (1986).
Brooks et al., "Effect of Castration, DES, Flutamide, and the 5alpha-Reductase
Inhibitor MK-906, on the Growth of the Dunning Rat Prostatic Carcinoma, R-3327", The
Prostate 18:215-227 (1991).
LaBrie et al., "Combination Therapy in Prostate Cancer", The Lancet Nov. 8,
1986, pp. 1095-1096.
Primary Examiner: Daus; Donald G.
Attorney, Agent or Firm: Fitch; Catherine D., Giesser; Joanne M., Winokur; Melvin
Abstract
Described are delta 17 and delta 20 olefinic and saturated 17 Beta-substituted 4-aza-5
alpha-androstan-3-ones and related compounds having 5 alpha reductase inhibitors for
treatment of benign prostatic hyperplasia and other hyperandrogenic related disorders.
14 Claims, No Drawings
content2 |
|
